21.06.2012 • NewscabotNoritMergers & Acquisitions (M&A)

Cabot to Buy Dutch Company Norit for $1.1 Billion

Chemicals maker Cabot said it will buy activated carbon manufacturer Norit for $1.1 billion as it moves its focus to higher-margin specialty chemicals.

Cabot will buy Netherlands-based Norit from affiliates of British private equity fund Doughty Hanson & Co Managers and Dutch investment firm Euroland Investments. Norit was acquired by a group of investors led by Doughty Hanson in 2007.

"This acquisition supports the ongoing transformation of our portfolio to a higher margin, less cyclical, specialty chemicals focused company," Cabot Chief Executive Patrick Prevost said.

Reuters reported in April that Norit, which had earlier announced plans for a U.S. initial public offering, was also exploring a sale of itself.

Activated carbon is generally derived from charcoal and used in purification and filtration processes. Norit sold its Clean Process Technologies unit to Pentair for €503 million last year.

Cabot expects the Norit deal to add 20 to 25 cents per share to its earnings, excluding one-time costs, in 2013.

Norit operates 10 plants throughout the Americas and Europe. It had sales of $360 million in 2 011.

J.P. Morgan was Cabot's financial adviser for the deal.

 

 

 

 

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.